Baraclude Related Published Studies
Well-designed clinical trials related to Baraclude (Entecavir)
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. [2011.07]
Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial. [2011.06]
Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients. [2011.05]
Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 Years. [2011.04]
Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. [2011.03]
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. [2011.01]
Pooled model-based approach to compare the pharmacokinetics of entecavir between
Japanese and non-Japanese chronic hepatitis B patients. [2011]
Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. [2010.11]
Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. [2010.06]
[Lamivudine and entecavir significantly improved the prognosis of early-to-mid stage hepatitis B related acute on chronic liver failure]. [2010.06]
[Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients] [2010.05]
A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. [2010.04]
Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. [2010.04]
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. [2010.03]
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. [2010.02]
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. [2010.01]
Food effect on the pharmacokinetics of entecavir from dispersible tablets following oral administration in healthy Chinese volunteers. [2010]
[Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients]. [2009.12]
Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance? [2009.03]
Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: phase II clinical study in Japan. [2009.02]
[Case-controlled study of entecavir treatment for chronic severe hepatitis B] [2009.02]
Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. [2009.01]
Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. [2008.11]
Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. [2008.09.12]
Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. [2008.09]
[Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China] [2008.09]
Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients. [2008.08]
Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: Randomized controlled trial in Japanese patients. [2008.06.12]
Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. [2008.01]
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. [2007.11]
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. [2007.03]
[Investigation of entecavir medication of chronic hepatitis B patients in the Chongqing area who failed lamivudine treatment.] [2007.01]
Entecavir resistance is rare in nucleoside naive patients with hepatitis B. [2006.12]
Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. [2006.11]
[A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B] [2006.11]
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. [2006.06]
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. [2006.03.09]
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. [2006.03.09]
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. [2005.10]
[A study of the dosage and efficacy of entecavir for treating hepatitis B virus] [2005.07]
Well-designed clinical trials possibly related to Baraclude (Entecavir)
Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. [2011.04]
Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. [2010.08]
Safety evaluation of telbivudine. [2010]
[Clinilal study of medical ozone therapy in chronic hepatitis B of 20 patients] [2008.12]
Other research related to Baraclude (Entecavir)
Entecavir versus lamivudine for the treatment of chronic hepatitis B: a
systematic review. [2012]
Comparison of the antiviral effects of entecavir and adefovir dipivoxil in
chronic HBV infection: a randomized control trial. [2012]
Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir
monotherapy, adefovir plus lamivudine or entecavir combination therapy. [2012]
Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant
chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. [2012]
Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. [2011.12.24]
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. [2011.08]
Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B. [2011.07]
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. [2011.06.22]
Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. [2011.05]
[Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients]. [2011.03]
[Long-term therapy with nucleoside analog entecavir (baraclude) in patients with chronic hepatitis B]. [2011]
Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. [2011]
[Study on the efficacy and HBeAg seroconversion related factors of telbivudine
and entecavir therapy in HBeAg positive chronic hepatitis B patients]. [Article in Chinese] [2011]
Randomized trial of lamivudine versus entecavir in entecavir-treated patients
with undetectable hepatitis B virus DNA: outcome at 2 Years. [2011]
Kinetics of hepatitis B surface antigen differ between treatment with
peginterferon and entecavir. [2011]
[The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review] [2010.08]
HBs seroconversion in a patient with acute hepatitis B treated with entecavir during immunosuppression against severe bronchiolitis obliterans in the course of chronic graft versus host disease. [2010.07]
Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-analyses. [2010.06.20]
Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: a case series. [2010.06]
[Genotypic resistance to entecavir in chronic hepatitis B patients] [2010.06]
Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. [2010.05]
Entecavir for hepatitis B virus flare treatment in patients with Crohn's disease. [2010.03]
Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies. [2010]
Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to
entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. [2010]
[Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir
therapy for chronic hepatitis B patients]. [Article in Chinese] [2010]
A 24-week, parallel-group, open-label, randomized clinical trial comparing the
early antiviral efficacy of telbivudine and entecavir in the treatment of
hepatitis B e antigen-positive chronic hepatitis B virus infection in adult
Chinese patients. [2010]
Entecavir treatment for up to 5 years in patients with hepatitis B e
antigen-positive chronic hepatitis B. [2010]
Early viral kinetics of telbivudine and entecavir: results of a 12-week
randomized exploratory study with patients with HBeAg-positive chronic hepatitis
B. [2010]
Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. [2009.11]
Entecavir for the treatment of chronic hepatitis B infection. [2009.10]
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B* [2009.07.19]
[A case of drug-induced liver injury caused by entecavir for treatment of hepatitis B virus reactivation during RCHOP in a patient with non-Hodgkin lymphoma] [2009.07]
Short-term entecavir therapy of chronic severe hepatitis B. [2009.06]
Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial. [2009.05.23]
[Five years trial of entecavir for chronic hepatitis B patients failed with lamivudine therapy in the Chongqing area] [2009.05]
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. [2009.05]
A combination treatment of entecavir and early-phase corticosteroid in severe exacerbation of chronic hepatitis B. [2009.04.07]
Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. [2009.04]
Portal pressure reduction after entecavir treatment in compensated HBV cirrhosis. [2009.01]
Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. [2009]
Entecavir: a review of its use in chronic hepatitis B. [2009]
Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. [2009]
[Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B] [2008.12]
Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. [2008.12]
Entecavir: a step forward in combating hepatitis B disease. [2008.12]
Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: a randomized, multicenter study. [2008.12]
[The clinic features and the short-term efficacy of entecavir treatment of the HBeAG negative acute-on-chronic hepatitis B liver failure] [2008.12]
Entecavir therapy in a hepatitis B-related decompensated cirrhotic patient. [2008.11]
Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients. [2008.10]
Pharmacoeconomics of entecavir treatment for chronic hepatitis B. [2008.10]
Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil. [2008.10]
Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. [2008.09.22]
Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. [2008.08.27]
Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis or Cirrhosis. [2008.08.21]
Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. [2008.08]
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. [2008.07]
Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks. [2008.06.08]
|
